Mirati Therapeutics
American biotechnology company
From Wikipedia, the free encyclopedia
Mirati Therapeutics, Inc. was an American targeted oncology company that focuses on the development of cancer therapeutics.[1] Bristol Myers Squibb acquired the company in January 2024.[2]
| Type | Subsidiary |
|---|---|
| |
| Industry | Oncology |
| Founded | 1995 |
| Headquarters | San Diego, California, U.S. |
Key people | David Meek |
Number of employees | 600 (2022) |
| Parent | Bristol Myers Squibb |
| Website | mirati |
History
Mirati Therapeutics worked largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.[3] The inhibition to the mutation has shown to shrink the size of its tumors.[4] The company was based in San Diego, California.[5] The company’s name came from the Italian word for “targeted” (Mirati). Mirati Therapeutics was traded on the Nasdaq[6] under the ticker symbol MRTX.[7] It joined the exchange in 2013.[8]
In October 2023, Bristol Myers Squibb agreed to acquire the company in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment.[9] The acquisition was completed in January 2024.[2]
Drug candidates
The company’s leading drug candidates are sitravatinib and adagrasib.[5] Mirati also has a preclinical candidate against the G12D mutation.[10]
Management
The company’s CEO and President was David Meek.[11]